

Evaluating 5-nitrothiazoles as trypanocidal agents

O'Shea, IP; Shahed, M; Aguilera-Venegas, B; WILKINSON, SR

http://aac.asm.org/content/early/2015/11/17/AAC.02006-15.long doi: 10.1128/AAC.02006-15

For additional information about this publication click this link. http://qmro.qmul.ac.uk/xmlui/handle/123456789/10016

Information about this research object was correct at the time of download; we occasionally make corrections to records, please therefore check the published record when citing. For more information contact scholarlycommunications@qmul.ac.uk

AAC Accepted Manuscript Posted Online 23 November 2015 Antimicrob. Agents Chemother. doi:10.1128/AAC.02006-15 Copyright © 2015, American Society for Microbiology. All Rights Reserved.

1	Evaluating 5-nitrothiazoles as trypanocidal agents
2	Ivan P. O'Shea ¹ , Mohammed Shahed ¹ , Benjamín Aguilera-Venegas ² and Shane R.
3	Wilkinson ¹ .
4	
5	¹ School of Biological and Chemical Sciences, Queen Mary University of London, London,
6	UK.
7	² Laboratory of Antioxidants, Institute of Nutrition and Food Technology, University of Chile,
8	Av. Macul 5540, Santiago, P.O. Box 138-11, Chile
9	
10	corresponding author: <u>s.r.wilkinson@qmul.ac.uk</u>
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	Running title: Anti-T. brucei activity of a nitrothiazole series
25	
26	

27 Abstract

The growth inhibitory properties of a 5-nitrothiazole series was evaluated against *Trypanosoma brucei*. A subset of related compounds displayed the greatest potency towards the parasite while exhibiting little cytotoxic effect on mammalian cells, with this antiparasitic activity being dependent on expression of a type I nitroreductase by the trypanosome. We conclude that the 5-nitrothiazole class of nitroheterocycle may represent new leads in the treatment of human African trypanosomiasis.

34

35 Spread via the blood feeding habits of tsetse flies, parasites belonging to the Trypanosoma brucei complex are responsible for human African trypanosomiasis (HAT) (1). Drugs 36 represent the only option to combat this infection but their use is often problematic (2). One 37 38 treatment that targets the cerebral stage of this disease is a nifurtimox-effornithine combination therapy (3, 4). In this medication effortithine acts as an inhibitor of ornithine 39 40 decarboxylase, blocking polyamine biosynthesis (5, 6) while nifurtimox is converted to a toxic metabolite following activation by a type I nitroreductase (NTR) (7, 8). As type I NTRs 41 are expressed by some unicellular eukaryotes but not by metazoan organisms, the 42 43 bioreductive activity of this enzyme has been exploited to develop a series of novel antiparasitic agents that often exhibit little or no toxicity towards cultured mammalian cells (9 & 44 45 10).

46

The 5-nitrothiazoles represent a class heterocyclic compounds of which niridazole and 47 nitazoxanide display potent antimicrobial and antihelmintic activities (11, 12). The mode(s) 48 of action of these agents is unclear with both structures shown to inhibit of key enzymes 49 50 involved in energy metabolism (13, 14) and able to function as prodrugs, undergoing reduction to form adduct forming metabolites (15-17). To date only niridazole and its 51 derivatives have been screened for trypanocidal activity against T. brucei with this in 52 combination with suramin able to cure mice of trypanosomiasis (18). However, concerns over 53 its carcinogenic properties resulted in trials using niridazole being suspended (19). Here, we 54 55 assessed a 2-amide 5-nitrothiazole series for growth inhibitory activity against bloodstream 56 form (BSF) T. brucei (Table 1). Out of the fifteen compounds tested, seven had no effect on trypanosomal growth at a concentration of 30 µM. For the remaining chemicals, detailed 57 inhibition assays were conducted generating dose response curves from which IC50s were 58 59 determined (Table 1). For NT2, NT4, NT6, NT7 and NT11 an appreciable trypanocidal

Antimicrobial Agents and Chemotherapy activity (IC₅₀'s >10.0 μ M) equivalent to the potency exhibited by nifurtimox was noted with the other agents being less effective (IC₅₀s ~17 μ M). Screening against two mammalian lines (Table 1) revealed that NT2, NT10, NT12 and NT15 displayed toxicity towards THP-1 or SK-N-SH cells with NT10 and NT12 having growth inhibitory effects against both lines. For the remaining agents no growth inhibitory effect at concentrations up to 100 μ M was observed.

66

Before mediating its trypanocidal effects nifurtimox must undergo activation in a reaction 67 catalysed by a type I NTR (7). Using purified HIS-tagged TbNTR (Fig. 1A) we evaluated 68 whether the 2-amide 5-nitrothiazoles series could serve as substrates for this enzyme (Fig. 69 70 1B). Five compounds were shown to be "good" NTR substrates, generating a specific activity ~3-fold greater than that noted for nifurtimox (Fig. 1B). Of these structures, NT2, NT4, NT6 71 and NT7 are related in that they contained a saturated unbranched hydrocarbon chain. 72 73 However, the number of carbon atoms in this sequence and the associated increase in 74 lipophilicity did not affecting the specific activity displayed by TbNTR towards a given substrate. Of the remaining compounds, three yielded activities similar to that observed for 75 nifurtimox while the others were not metabolised by TbNTR at an appreciable rate under the 76 77 conditions used here (Fig. 1B).

78

To investigate whether NTR plays a role in prodrug activation within the parasite itself the susceptibility of BSF *T. brucei* engineered to over express this enzyme was evaluated (Table 1; Fig. 2) (8). Cells having elevated levels of TbNTR were up to 10-fold more sensitive to NT2, NT4, NT6 or NT7 than controls. This effect was NTR specific as recombinant and wild type parasite lines displayed similar sensitivities to the non-nitroaromatic compound G418 ($IC_{50} \sim 0.6 \mu M$). When these studies were extended to test other trypanocidal nitrothiazoles, a lower (~2) fold or no difference in IC_{50} was observed (Table 1; Fig. 2). This implies that for these less effective trypanocidal compounds, NTR plays little or no role in the metabolism of these structures within the parasite itself.

88

By comparing the specific activity values and growth inhibitory effects of each compound, a 89 90 number of structure activity relationships (SARs) were identified. In contrast to their nonsubstituent counterparts' addition of a methyl or *tert*-butyl group at the 4-position on the 91 thiazole ring generated compounds that were not TbNTR substrates and did not exhibit 92 trypanocidal activities: compare NT2 with NT3 and NT4 with NT5. This lack of activity 93 could be due to steric hindrance with the 4-alkyl side chain blocking the trypanosomal 94 95 enzyme from gain access to the adjacent 5-nitro grouping or could reflect an inductive effect with the alkyl substituent on the thiazole backbone rendering nitroreduction energetically 96 unfavourable. Extending the SAR studies to investigate grouping attached to the thiazole ring 97 via a 2-amide linker revealed that compounds containing an unbranched, saturated 98 99 hydrocarbon chain (NT2, NT4, NT6, NT7) were efficiently metabolised by TbNTR with this 100 translating to a trypanocidal effect equivalent to that of the reference nitrofuran. Encouragingly, these structures displayed also little/no in vitro toxicity to mammalian cells 101 102 suggesting that they warrant in vivo analysis. Modification of this saturated linear hydrocarbon chain (incorporation of an unsaturated bond (NT8) or an ether linkage (NT13), 103 inclusion of halogen substituents (NT10-12) or its replacement with a hydrogen atom (NT1) 104 or a benzyl-containing grouping (NT9, NT15)) generated structures that displayed lower 105 TbNTR activity and/or had reduced potency towards BSF trypanosomes. Presumably, such 106 107 alterations to the saturated alkyl chain alter the affinity these variants have for the parasite oxidoreductase. As the broad spectrum ant-infective agent nitazoxanide is structurally related 108 109 to NT9 and NT15 (all contain a phenyl group attached to the amide linker) we predict that

AAC

this particular antimicrobial agent is unlikely to function as an effective TbNTR substrate
and/or display activity against BSF *T. brucei*. Intriguingly, despite being screened against a
wide range of microbial infectious agents including *Trypanosoma cruzi* and *Leishmania* the
potency of this particular nitrothiazole against *T. brucei* has not been reported.

114

115 There has been renewed interest in the use of nitroheterocyclic prodrugs for the treatment of trypanosomatid infections with nifurtimox in combination with effornithine now being used 116 to treat the form of HAT prevalent in West and Central Africa while the nitroimidazole 117 fexinidazole is under clinical evaluation against HAT, Chagas disease and visceral 118 leishmaniasis. In both cases these nitroheterocycles are converted to toxic metabolites by a 119 type I NTR activity (7, 20). Here, we have identified several trypanocidal nitrothiazoles, 120 including some that are activated by the type I NTR, as being potent against BSF T. brucei as 121 nifurtimox. Promisingly the most effective structures exhibited little or no toxicity to cultured 122 mammalian cells with trypanosomal expression of the type I NTR underlying their 123 selectivity. As such, these compounds warrant further attention in terms of developing novel 124 therapies targeting HAT and could potentially represent one component of a new 125 combinatorial treatment against this disease. 126

127

128 Funding Information

129 BAV acknowledges financial support by FONDECYT Postdoctorado 3130364.

130

131 Acknowledgments

132 We would like to thank Martin Taylor (London School of Hygiene and Tropical Medicine)

and James Sullivan (Queen Mary University of London) for valuable discussions andcomments on the manuscript.

135

136 Abbreviations.

137 BSF, bloodstream form; HAT, human African trypanosomiasis; NECT, nifurtimox-

138 effornithine combination therapy; NTR, nitroreductase; SAR, structure activity relationship;

139 TbNTR, Trypanosoma brucei type I nitroreductase

140

141

142 **References**

Brun R, Blum J, Chappuis F, Burri C. 2010. Human African trypanosomiasis. Lancet 375:148-159.

Wilkinson SR, Kelly JM. 2009. Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev Mol Med. 11:e31.

Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U,
 Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, Ilunga M, Mutangala W,
 Pohlig G, Schmid C, Karunakara U, Torreele E, Kande V. 2009. Nifurtimox eflornithine combination therapy for second-stage African *Trypanosoma brucei* gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
 Lancet. 374:56-64.

- Yun O, Priotto G, Tong J, Flevaud L, Chappuis F. 2010. NECT is next:
 implementing the new drug combination therapy for *Trypanosoma brucei gambiense* sleeping sickness. PLoS Negl. Trop. Dis. 4:e720.
- Bacchi CJ, Nathan HC, Hutner SH, McCann PP, Sjoerdsma A. 1980. Polyamine
 metabolism: a potential therapeutic target in trypanosomes. Science. 210:332-334.


Willert EK, Phillips MA. 2008. Regulated expression of an essential allosteric
 activator of polyamine biosynthesis in African trypanosomes. PLoS Pathog.
 4:e1000183.

- 161 7. Hall BS, Bot C, Wilkinson SR. 2011. Nifurtimox activation by trypanosomal type I
 162 nitroreductases generates cytotoxic nitrile metabolites. J. Biol. Chem. 286:13088163 13095.
- Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I. 2008. A mechanism
 for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl.
 Acad. Sci. USA. 105:5022-5027.

167 9. Wilkinson SR, Bot C, Kelly JM, Hall BS. 2011. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives. Curr Top Med 168 Chem. 11:2072-2084. 169 10. Patterson S, Wyllie S. 2014. Nitro drugs for the treatment of trypanosomatid 170 diseases: past, present, and future prospects. Trends Parasitol. 30:289-98 171 172 11. Archer S. 1985. The chemotherapy of schistosomiasis. Annu. Rev. Pharmacol. Toxicol. 25:485-508. 173 12. Hemphill A, Mueller J, Esposito M. 2006. Nitazoxanide, a broad-spectrum 174 175 thiazolide anti-infective agent for the treatment of gastrointestinal infections. Expert Opin. Pharmacother. 7:953-964. 176 177 13. Bueding E, Fisher J. 1970. Biochemical effects of niridazole on Schistosoma mansoni. Mol Pharmacol. 6:532-9. 178 14. Hoffman PS, Sisson G, Croxen MA, Welch K, Harman WD, Cremades N, 179 Morash MG. 2007.. Antiparasitic drug nitazoxanide inhibits the pyruvate 180 oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and 181 182 Campylobacter jejuni. Antimicrob. Agents Chemother. 51:868-876. 15. Blumer JL, Friedman A, Meyer LW, Fairchild E, Webster LT, Jr., Speck WT. 183 1980. Relative importance of bacterial and mammalian nitroreductases for niridazole 184 mutagenesis. Cancer Res. 40:4599-4605. 185 16. Tracy JW, Catto BA, Webster LT, Jr. 1983. Reductive metabolism of niridazole by 186 187 adult Schistosoma mansoni. Correlation with covalent drug binding to parasite 188 macromolecules. Mol. Pharmacol. 24:291-299. 17. Muller J, Wastling J, Sanderson S, Muller N, Hemphill A. 2007. A novel Giardia 189 lamblia nitroreductase, GlNR1, interacts with nitazoxanide and other thiazolides. 190 191 Antimicrob. Agents Chemother. 51:1979-1986.

192	18. Jennings FW. 1987. Chemotherapy of late-stage trypanosomiasis: the effect of the
193	nitrothiazole compounds. Trans. R. Soc. Trop. Med. Hyg. 81:616.
194	19. Bulay O, Urman H, Clayson DB, Shubik P. 1977. Carcinogenic effects of
195	niridazole on rodents infected with Schistosoma mansoni. J. Natl. Cancer Inst.
196	59 :1625-1630.
197	20. Wyllie S, Patterson S, Stojanovski L, Simeons FR, Norval S, Kime R, Read KD,
198	Fairlamb AH. 2012. The anti-trypanosome drug fexinidazole shows potential for
199	treating visceral leishmaniasis. Sci. Transl. Med. 4:119re1.

200**Table 1. Structure and growth inhibitory properties of nitrothiazole compounds.** All compounds tested satisfy the Lipinski's Rule of 5 (see201PubChem database (http://pubchem.ncbi.nlm.nih.gov/). Susceptibility of parasites and mammalian cells to nitrothiazole compounds was202assessed as previously described (7). Average ICs0 values \pm standard deviations were calculated from dose response curves performed in203triplicate. TbNTR^{ox} represents the *T. brucei* cell line overexpressing the type I nitroreductase. The figures in parenthesis correspond to the fold204difference in ICs0 values of the TbNTR^{ox}, SK-N-SH and THP-1 cell lines when compared against wild type.205



compound	Structure		IC ₅₀ (µM)			
			T. brucei		Mammalian line	
	R ₁	R ₂	wild type	TbNTR^{ox}	SK-N-SH	THP-1
NT1	Н	Н	>30.00			
NT2	CH ₃	Н	4.67 ± 0.34	0.58 ± 0.11 (8)	>100.00 (>21)	86.97 ± 0.99 (19)
NT3	CH ₃	CH ₃	>30.00			
NT4	CH ₂ CH ₃	Н	3.67 ± 0.50	0.51 ± 0.09 (7)	>100.00 (>27)	>100.00 (>27)
NT5	CH ₂ CH ₃	$C(CH_3)_3$	>30.00			
NT6	CH ₂ CH ₂ CH ₃	Н	6.47 ± 0.06	0.64 ± 0.13 (10)	>100.00 (>15)	>100.00 (>15)
NT7	CH ₂ CH ₂ CH ₂ CH ₃	Н	4.32 ± 0.90	0.57 ± 0.02 (8)	>100.00 (>23)	>100.00 (>23)
NT8	CH ₂ CHCH ₂	Н	>30.00			
NT9	benzyl	Н	>30.00			
NT10	CH ₂ Cl	Н	16.12 ± 0.97	$13.53 \pm 0.50(1)$	$18.33 \pm 0.68 (1)$	7.68 ± 0.56 (<1)
NT11	$C(F)_3$	Н	8.87 ± 0.70	$11.24 \pm 0.58(1)$	>100.00 (>11)	>100.00 (>11)
NT12	CH(Br)CH ₃	Н	17.41 ± 1.08	$8.37 \pm 1.84(2)$	$19.83 \pm 0.44(1)$	$21.53 \pm 0.19(1)$
NT13	CH ₂ OCH ₃	Н	>30.00			
NT14	C(CH ₃) ₂ CH ₃	CH ₃	>30.00			
NT15	3,5 dichlorobenzyl	Н	16.26 ± 1.24	8.17 ± 0.61 (2)	>100.00 (>6)	$6.75 \pm 1.08 (<1)$
NFX			4.12 ± 0.13	$0.31 \pm 0.06(13)$	>100.00 (>24)	$64.80 \pm 1.50(16)$

206

Antimicrobial Agents and Chemotherapy




Figure 1. Activity of TbNTR toward different nitrothiazoles. (A) Samples obtained during purification of recombinant TbNTR were analysed on by SDS-PAGE (10 %) stained with Coomassie blue. *E. coli* crude extract (lane 1) was loaded onto a Ni-NTA column and the flow through (lane 2) collected. The column was washed with 50 mM imidazole (lane 3) and 100 mM imidazole (lane 4) containing buffers. Recombinant protein was eluted in a buffer containing 500 mM imidazole; 0.5 % Triton X-100 (lane 5). Markers (M) are in kiloDaltons. The ~30 kDa band corresponding to recombinant TbNTR is indicated. (B) Activity of purified recombinant TbNTR was assessed by using nitrothiazoles (NT1-15) as substrate (100 μ M) at a fixed concentration of NADH (100 μ M). Enzyme activity, expressed in nmoles of NADH oxidised per minute per mg TbNTR, was then calculated using an ε value of 6,220 M⁻¹ cm⁻¹. Nfx (nifurtimox) was used as control and enzyme activity determined as previously described (7). The enzyme activity values are the means of data from 3 assays \pm standard deviations.

Antimicrobial Agents and Chemotherapy




Figure 2. Susceptibility of bloodstream form *T. brucei* over expressing TbNTR to nitrothiazoles. Dose-response curves of *T. brucei* (solid line) and parasites expressing an ectopic copy of Tb*ntr* (dashed line) towards representative nitrothiazoles. The growth inhibitory effect expressed as IC_{50} values was determined (see Table 2). All data points are mean values ± standard deviations from experiments performed in quadruplicate. Nifurtimox was used as drug control.

AAC